Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant

Not Recruiting

Trial ID: NCT01759862

Age - 1 Year-21 Years Gender - All Accepting Healthy Volunteers - No

Purpose

The aim of this study is to evaluate whether peri-transplant administration of a drug named aminophylline to children undergoing a kidney transplant from deceased donors improves early graft function and also projects on long term graft function.

Official Title

Perioperative Aminophylline to Improve High Risk Renal Graft Outcome- a Double Blinded, Placebo Controlled, Randomized Clinical Trial

Stanford Investigator(s)

Paul C. Grimm

Eligibility


Inclusion Criteria:

   1. Pediatric kidney transplant recipients less than 21 years of age

   2. Patients undergoing deceased donor (DD) kidney transplants

Exclusion Criteria:

   1. Known history of non-sinus tachycardia

   2. Multiple organ transplants recipients

   3. Severe liver dysfunction

   4. graft was placed on pump after harvesting

View More
View Less

Intervention(s):

drug: Aminophylline

other: Theophylline drug levels

drug: Placebo

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Vivian Shih, MD
650-723-7903

©2024 Stanford Medicine